Trial intelligence / Profile preview

Phase III randomized trial of desmoteplase in acute ischemic stroke (3–9 hours after onset)

2008-005539-14Phase 3Completed

Sponsor
Lundbeck
Start
Nov 2008
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in ischemic stroke comparing Desmoteplase 90 µg/kg with Placebo (2 arms). Primary endpoint: Favourable functional outcome at Day 90. Started Nov 2008; status: completed.

02

Drugs

desmoteplase
03

Conditions

ischemic stroke

Beyond the preview

Go deeper on 2008-005539-14.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-005539-14.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call